Veritable’s Celldex Therapeutics CLDX Stock Holding History

Veritable’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-2,000	Closed	-$132K	–	730
2016 Q2	$132K	Buy	+2,000	New	+$127K	﹤0.01%	694

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Veritable's CLDX Position: Q3 2016 in Review

Veritable sold out of Celldex Therapeutics (CLDX) in Q3 2016, closing a stake of 2,000 shares — an estimated $132K sold.

Veritable first reported a position in CLDX in Q2 2016 and held it in 1 quarter. The position peaked at $132K in Q2 2016. 139 funds tracked by Wall St. Rank hold CLDX as of Q3 2016.

Veritable reported no remaining Celldex Therapeutics position as of Q3 2016 after selling out during the quarter.
Veritable sold 2,000 Celldex Therapeutics shares in Q3 2016, an estimated $132K.
Veritable first reported a position in Celldex Therapeutics in Q2 2016 and held it in 1 quarter.
Veritable's Celldex Therapeutics position peaked at $132K in Q2 2016.
139 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2016.

Based on Veritable's 13F filing for Q3 2016, filed 14 Nov 2016.